Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation

Clinical Transplantation

Volumn 25, Issue 4, 2011, Pages 517-522

  Yuefeng, M ^a   Weili, F U ^a   Wenxiang, T ^a   Ligang, X ^a   Guiling, L ^a   Hongwei, G ^a   Wencai, L ^a   Xiaoguang, W ^a   Wei, M ^a   Zhongyi, F ^a  

^a Dalian Friendship Hospital   (China)

Author keywords

Hepatitis B; Hepatitis B immunoglobulin; Lamivudine; Liver transplantation

Indexed keywords

ADEFOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 80051704274     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01290.x     Document Type: Article

References (25)

1. Todo S, Demetris AJ, Van Thiel D et al. Orthotopic liver transplantation for patients with hepatitis B virusrelated liver disease. Hepatology 1991: 13: 619.
2. O'Grady JG, Smith HM, Davies SE et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992: 14: 104.
3. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with hepatitis B surface antigen. N Engl J Med 1993: 329: 1842.
4. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998: 28: 585.
5. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004: 10(Suppl 2): S74.
6. Bui Han SH, Martin P. Liver transplantation for hepatitis B. Hepatol Res 2004: 29: 193.
7. Steinmuller T, Seehofer D, Rayes N et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002: 35: 1528.
8. Kim WR, Poterucha JJ, Kremers WK et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004: 10: 968.
9. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplanation setting: a European and a American Perspective. Liver Transpl 2005: 11: 716.
10. Roche B, Samuel D. Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results. J Hepatol 2003: 39: S181.
11. Dodson SF, De Vera ME, Bonham CA et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000: 6: 434.
12. Naoumov NV, Lopes AR, Burra P et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001: 34: 888.
13. Buti M, Mas A, Prieto M et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003: 38: 811.
14. Buti M, Mas A, Prieto M et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007: 84: 650.
15. Yoshida H, Kato T, Levi DM et al. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin Transplant 2007: 21: 166.
16. Wong SN, Chu CJ, Wai CT et al. Low risk of hepatitis B virus recurrence after withdrawal of longtermhepatitis B immunoglobulin patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007: 13: 374.
17. Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996: 24: 1327.
18. Carman WF, Owsianka A, Wallace LA et al. Antigenic characterisation of pre- and post-liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin. J Hepatol 1999: 31: 195.
19. Noborg U, Gusdal A, Horal P, Lindh M. Levels of viraemia in subjects with serological markers of past or chronic hepatitis B virus infection. Scand J Infect Dis 2000: 32: 249.
20. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998: 339: 61.
21. Honkoop P, Niesters HG, De Man RA et al. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997: 26: 1393.
22. Liaw YF, Chien RN, Yeh CT et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999: 30: 567.
23. Ireland JH, O'Donnell B, Basuni AA et al. Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. Hepatology 2000: 31: 1176.
24. Shouval D, Samuel D. Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology 2000: 32: 1189.
25. Marzano A, Gaia S, Ghisetti V et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005: 11: 402.